Tafasitamab is a targeted antibody therapy used in the treatment of certain adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). For patients in India who require this treatment, obtaining the medicine may involve additional steps when it is not readily accessible through regular pharmaceutical distribution channels. Understanding its therapeutic use, prescription requirements, import documentation and available access pathways can help patients and caregivers plan the process more effectively.
Tafasitamab, marketed under the brand name Monjuvi in the United States and Minjuvi® in certain other markets, may be accessed through an appropriate Named Patient Supply (NPS) arrangement, subject to applicable Indian import regulations and approvals. This pathway is intended to facilitate access to medicines for individual patients when they cannot obtain the required treatment through conventional channels.
Understanding Tafasitamab and Its Therapeutic Use
Tafasitamab-cxix is an Fc-modified monoclonal antibody developed using recombinant DNA technology in mammalian cells. It specifically binds to the CD19 antigen, a protein expressed on the surface of pre-B cells, mature B lymphocytes and several types of B-cell malignancies, including diffuse large B-cell lymphoma.
By attaching to CD19, tafasitamab helps trigger the destruction of malignant B cells through different immune-mediated mechanisms. These include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and apoptosis. When administered alongside lenalidomide, tafasitamab has demonstrated increased ADCC activity in laboratory studies compared with either treatment used individually. This targeted mechanism makes tafasitamab an important treatment option for certain patients whose DLBCL has returned after previous treatment or has not responded adequately to therapy.
Who is Tafasitamab Prescribed For?
Tafasitamab, in combination with lenalidomide, is indicated for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL that has developed from a previously diagnosed low-grade lymphoma. The combination is intended for patients who are not eligible for autologous stem cell transplantation (ASCT). This treatment may be considered when the disease progresses or returns following earlier therapy and the patient is not a suitable candidate for this transplant procedure.
The treatment indication was initially granted under accelerated approval based on overall response rate. Continued approval for this indication may depend on confirmation of clinical benefit through additional clinical trials. Treatment suitability must be assessed by an oncologist or haematologist after considering the patient’s diagnosis, previous treatments, disease status and overall health.
How is Tafasitamab Administered?
Tafasitamab is given as an intravenous infusion by a qualified healthcare professional. The recommended dosage is 12 mg/kg of actual body weight, following the administration schedule specified in the FDA approved prescribing information.
It is initially administered in combination with lenalidomide at a recommended dose of 25 mg for a maximum of 12 treatment cycles. After completion of the combination phase, tafasitamab may be continued as a single-agent treatment until disease progression or unacceptable toxicity occurs. Since infusion-related reactions are possible, administration must take place in a healthcare setting with appropriate medical supervision and access to emergency equipment. The treating physician determines the dosing schedule, monitors treatment response and makes any necessary adjustments during therapy.
Potential Side Effects and Important Safety Considerations
Although tafasitamab is designed to target CD19-expressing cells, treatment can also affect normal B cells and blood cell counts. Patients receiving this therapy require regular medical supervision to identify and manage possible adverse reactions. Some important safety considerations include:
- Infusion-related reactions: Reactions may occur during or following administration. Patients should be monitored during infusions, and appropriate medical support should be available.
- Myelosuppression: Tafasitamab treatment may cause reductions in blood cell counts. Regular blood tests help monitor these changes and guide treatment decisions.
- Infections: Patients may develop bacterial, viral or fungal infections during treatment. Any signs of infection should be reported to the treating healthcare professional.
- Pregnancy and reproductive health: Tafasitamab may cause fetal B-cell depletion when administered during pregnancy. Lenalidomide is associated with embryo-fetal toxicity and should not be used during pregnancy. Effective contraception is advised for females and males of reproductive potential during treatment and for at least three months after the final tafasitamab dose.
- Breastfeeding: Breastfeeding is not recommended during treatment or for at least three months after the last dose because of the potential risk of adverse reactions in breastfed children.
- The safety and effectiveness of tafasitamab in children have not been established. Older patients may also require careful monitoring, particularly because more severe adverse reactions were observed in patients aged 65 years and above in the clinical studies.
Tafasitamab Storage and Handling Requirements
Tafasitamab is supplied as a sterile, preservative-free, white to slightly yellowish lyophilized powder for reconstitution. Each single-dose vial contains 200 mg of tafasitamab-cxix. The medicine must be stored under refrigerated conditions between 2°C and 8°C, preferably in its original carton to protect it from light. It must not be frozen or shaken.
Since tafasitamab is administered intravenously, preparation and handling should be performed by trained healthcare professionals following the manufacturer’s instructions. Appropriate storage and temperature control during international transportation are also important considerations when arranging an imported supply.
Availability of Tafasitamab in India
Accessing tafasitamab in India may require an individual import arrangement if the medicine is not available through the patient’s regular hospital or pharmacy supply channels. Unlike commonly prescribed medicines, specialized oncology therapies may need to be sourced internationally to meet an individual patient’s treatment requirements.
For patients who have been prescribed tafasitamab, the Named Patient Supply (NPS) pathway can help coordinate access through international sourcing and the applicable personal-use import procedure. The process generally involves obtaining the treating physician’s prescription, collecting the necessary medical records, verifying the import requirements and coordinating procurement with an international supplier.
Tafasitamab should only be supplied against a valid medical prescription. Patients and caregivers should avoid purchasing the medicine through unverified sellers or informal distribution channels, particularly because the product requires controlled storage and appropriate handling.
Importing Tafasitamab through the Named Patient Supply Program
The Named Patient Supply pathway facilitates access to medicines required by individual patients when those medicines cannot be obtained through conventional local supply channels.
In India, the import of small quantities of medicines for personal use is addressed under Rule 36 of the Drugs and Cosmetics Rules, 1945. The applicable procedure may involve submitting an application in Form 12A to the Central Drugs Standard Control Organisation (CDSCO). Where the application is approved, the corresponding import permit is issued in Form 12B. This distinction is important: submitting Form 12A does not automatically authorize the import. The required permission must be obtained before proceeding under the applicable route.
Steps Involved in the Import Process
- Submission of the medicine request: The patient or caregiver initiates the process by submitting a request for tafasitamab. The request should include the doctor’s prescription, diagnosis and relevant treatment details.
- Preparation of Form 12A: The required application for personal-use importation is prepared along with the prescription issued by a Registered Medical Practitioner (RMP). The application must specify the medicine and the quantity required for treatment.
- Medical document verification: The submitted prescription and supporting medical records are reviewed to establish the patient’s medical requirement and confirm that the proposed import is intended for personal treatment.
- Regulatory review and import permission: The application is submitted to the relevant regulatory authority for consideration. Once the necessary permission is granted, the import process can proceed in accordance with the approved requirements.
- International medicine procurement: After the necessary approvals and documentation checks, procurement specialists coordinate with international suppliers to source tafasitamab. Supplier verification and product checks are important to help ensure medicine authenticity and appropriate quality.
- Shipping and delivery in India: Once procurement and shipment arrangements are completed, the medicine is transported to India with attention to applicable import requirements and storage conditions. Delivery is coordinated to ensure that the product reaches the intended patient or designated healthcare facility.
The CDSCO provides an online Form 12A application facility through its SUGAM portal, along with information on personal-use drug imports.
Documents Required to Import Tafasitamab into India
Patients or caregivers arranging an international supply of tafasitamab may need to submit several documents to support the personal-use import application. Having these records ready can help avoid unnecessary delays during verification and processing. The commonly required documents include:
- Valid medical prescription: A prescription from a Registered Medical Practitioner specifying tafasitamab, the prescribed dosage, treatment duration and medical diagnosis.
- Medical history and diagnostic reports: Recent clinical records, preferably from the last three months, supporting the diagnosis and explaining the need for treatment.
- Patient identification: A government-issued identity document for patient verification.
- Proof of residence: An address document to establish the patient’s residential details and facilitate delivery.
- Form 12A application: The prescribed application for permission to import small quantities of medicines for personal use.
- Import permit: The applicable authorization issued following regulatory approval, where required.
Additional documents or clarifications may be requested depending on the patient’s circumstances and the applicable import requirements. The CDSCO’s official Form 12A process requires a prescription from a registered medical practitioner.
Tafasitamab Price in India and Supply Considerations
The tafasitamab price in India can vary depending on the country of origin, international supplier availability, procurement costs and import-related expenses. Since the medicine may need to be sourced from overseas, the final quotation can also be influenced by shipping charges, applicable taxes, currency exchange rates and documentation requirements. There may not be a single fixed price applicable to every patient or import request. The quantity required will depend on the prescribed dosage, the patient’s body weight and the treatment schedule determined by the oncologist.
Patients seeking to buy tafasitamab in India can request an individual price quotation after submitting the prescription and necessary medical documents. This allows the procurement team to assess the required quantity, check international availability and calculate the associated import and delivery costs.
Arranging Tafasitamab Supply Across India
For patients who cannot source tafasitamab locally, international procurement and import coordination can help facilitate access to the prescribed treatment. Through 247QualityMeds, patients and caregivers can enquire about tafasitamab availability, pricing and import assistance in India. The process involves prescription verification, documentation review, coordination with international suppliers and shipment arrangements. Each request is evaluated according to the patient’s medical requirements and applicable regulatory procedures.
Patients are encouraged to confirm the product’s availability, expected procurement timelines, storage requirements and total cost before placing an order. All supply arrangements should be supported by the necessary medical documentation and import permissions.
For tafasitamab pricing and availability, patients can visit 247QualityMeds support team at +91 9967979080 and contact the for assistance with their medicine request.
Conclusion
Tafasitamab offers a targeted treatment option for eligible adults with relapsed or refractory diffuse large B-cell lymphoma. However, obtaining the medicine in India may require additional planning when local supply is limited or unavailable. Understanding the Named Patient Supply arrangement, personal-use import requirements, prescription documentation and international procurement process can help patients and caregivers navigate access more effectively.
With the appropriate medical prescription, regulatory permission and coordination with reliable international suppliers, patients can explore a structured route for importing tafasitamab into India. Throughout the process, maintaining product authenticity, appropriate storage conditions and compliance with applicable import requirements remains essential.
